NEMUS Bioscience (OTCQB: NMUS) this morning said it is moving forward with Catalent Pharma Solutions to advance development of a human-dosage suppository formulation of NB1222. NB1222 is the proprietary prodrug of tetrahydrocannabinol (THC) being developed for the treatment and management of chemotherapy-induced nausea and vomiting (CINV). NB1222, also known as the prodrug THC-valine-hemisuccinate, is synthetically manufactured and is not plant-derived. “The global CINV market is a multi-billion dollar opportunity with projected growth as populations live longer, increasing the likelihood of developing a malignancy over time,” Nemus CEO and chief medical officer Brian Murphy, M.D. stated in the news release.
To view the full press release, visit: http://nnw.fm/ey9VH
About NEMUS Bioscience, Inc.
Nemus Bioscience, Inc. is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting potential adverse events. NEMUS’s strategy is to explore the use of natural and synthetic compounds, alone or in combination with partners. The company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development. For more information, visit www.nemusbioscience.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of CannabisNewsWire (CNW). NNB keeps you up-to-date on active US Public Companies complementary to CNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, CNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information, visit https://www.CannabisNewsWire.com.
Please see full disclaimers on the CannabisNewsWire website: http://nnw.fm/Disclaimer